Cargando…
S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812070/ http://dx.doi.org/10.1097/01.HS9.0000821456.11824.0b |
| _version_ | 1784644569143443456 |
|---|---|
| author | Heeney, M Rees, D de Montalembert, M Odame, I Brown, C Wali, Y Nguyen, T Lam, D Pfender, N Kanter, J |
| author_facet | Heeney, M Rees, D de Montalembert, M Odame, I Brown, C Wali, Y Nguyen, T Lam, D Pfender, N Kanter, J |
| author_sort | Heeney, M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8812070 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88120702022-02-18 S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL Heeney, M Rees, D de Montalembert, M Odame, I Brown, C Wali, Y Nguyen, T Lam, D Pfender, N Kanter, J Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8812070/ http://dx.doi.org/10.1097/01.HS9.0000821456.11824.0b Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Presentations Heeney, M Rees, D de Montalembert, M Odame, I Brown, C Wali, Y Nguyen, T Lam, D Pfender, N Kanter, J S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title | S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title_full | S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title_fullStr | S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title_full_unstemmed | S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title_short | S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL |
| title_sort | s122: safety and efficacy of crizanlizumab in adolescents with sickle cell disease (scd): initial data from the phase ii, multicenter, open-label solace-kids trial |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812070/ http://dx.doi.org/10.1097/01.HS9.0000821456.11824.0b |
| work_keys_str_mv | AT heeneym s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT reesd s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT demontalembertm s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT odamei s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT brownc s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT waliy s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT nguyent s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT lamd s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT pfendern s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial AT kanterj s122safetyandefficacyofcrizanlizumabinadolescentswithsicklecelldiseasescdinitialdatafromthephaseiimulticenteropenlabelsolacekidstrial |